SCHEMBL24728445

SCHEMBL24728445

c1ccc(-c2ccc(Nc3cccc4c3-c3ccccc3C43C4CC5CC(C4)CC3C5)cc2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
STK10 O94804 1/20 0.34
SLK Q9H2G2 1/20 0.34
AKR1C3 P42330 1/20 0.33
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
MET P08581 2/20 0.31
HGF P14210 2/20 0.31
HSD11B1 P28845 1/20 0.31
KDM4E B2RXH2 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
RECQL P46063 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25452127 1.00 SIGMAR1 (0.34) SIGMAR1MEN1KMT2ANPSR1STK10
SCHEMBL22799493 0.96 MET (0.34) SIGMAR1MEN1KMT2ANPSR1STK10
SCHEMBL22797226 0.96 SIGMAR1 (0.36) SIGMAR1MEN1KMT2ANPSR1STK10
SCHEMBL24728353 0.92 MEN1 (0.37) SIGMAR1MEN1KMT2ANPSR1MAPK14
SCHEMBL22799310 0.91 SIRT2 (0.39) SIGMAR1MEN1KMT2ANPSR1STK10
SCHEMBL25452097 0.90 PDK2 (0.37) SIGMAR1STK10SLKHSD11B1PDK2
SCHEMBL22799462 0.90 SIRT2 (0.38) SIGMAR1MEN1KMT2ANPSR1STK10
SCHEMBL22797636 0.88 SIGMAR1 (0.41) SIGMAR1MEN1KMT2ANPSR1PDK2
SCHEMBL22799320 0.87 SIGMAR1 (0.35) SIGMAR1MEN1KMT2ANPSR1AKR1C3
SCHEMBL23959417 0.87 PDK2 (0.34) STK10SLKPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146030-A1 ARYLAMINE COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-05-11 US disclosed
US-20230146030-A1 ARYLAMINE COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-05-11 US disclosed
US-20220388944-A1 NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2022-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146030-A1 ARYLAMINE COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE OCIAD2, AOC2, OCIAD1 SIGMAR1 890/4885MEN1 3876/4885KMT2A 850/4885
US-20220388944-A1 NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS NOM1, MNS1, NOS1 SIGMAR1 1026/4885MEN1 697/4885KMT2A 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.